Dana-Farber Cancer Institute | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana-Farber Cancer Institute

From Targetless to Targetable, Breakthroughs Push Forward in TNBC Treatment Landscape

July 26, 2024

Article

Sara M. Tolaney, MD, MPH, discusses the transformation of treatments for patients with triple-negative breast cancer.

Changes in HER2+ Breast Cancer May Include Tailored Therapy With pCR, Use of T-DXd

July 26, 2024

Article

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.

Dr Sands on the Evolving Role of ADCs in SCLC Management

July 25, 2024

Video

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Dr Morgans on the Relationship Between PSA Levels and Radiographic Progression in nmCRPC

July 25, 2024

Video

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

July 25, 2024

Article

Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

July 25, 2024

Video

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer

July 24, 2024

Article

Paolo Tarantino, MD, discusses questions about the optimal sequencing of antibody-drug conjugates in endocrine-refractory, HR-positive breast cancer.

Dr Tolaney on the Development of Mutation-Selective PI3K Inhibitors in Breast Cancer

July 24, 2024

Video

Sara M. Tolaney, MD, MPH, discusses the ongoing development of mutation-selective PI3K inhibitors in PI3K-mutant metastatic breast cancer.

Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line

July 24, 2024

Article

Adrienne G. Waks, MD, details her approach to treatment sequencing in metastatic HER2-positive disease and the potential role of T-DXd in the first line.

Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?

July 23, 2024

Article

Adrienne G. Waks, MD, parses out recent and upcoming data in HER2+ breast cancer and discusses why abbreviated neoadjuvant regimens are not ready for primetime.

Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium

July 22, 2024

Article

Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management

July 22, 2024

Article

Circulating tumor DNA is in constant flux, rendering its evaluation potentially useful in metastatic breast cancer management.

De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer

July 20, 2024

Article

Sara M. Tolaney, MD, MPH, discusses the use of HER2-directed therapy in the curative setting for HER2-positive breast cancer.

Dr Morgans on the Importance of Detecting Radiographic Progression in nmCRPC

July 19, 2024

Video

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast Cancer

July 17, 2024

Video

Adrienne G. Waks, MD, discusses implications of the potential use of first-line T-DXd in HER2-positive breast cancer.

Abemaciclib Monotherapy Does Not Elicit Responses in Advanced Renal Cell Carcinoma

July 12, 2024

Article

Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.

Belzutifan Shows Manageable, Pooled Safety Profile in Advanced VHL-Associated RCC

July 12, 2024

Article

Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.

Dr McGregor on the Data for Abemaciclib in Advanced ccRCC

July 12, 2024

Video

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Researchers Report First Effective Use of Immunotherapy for Most Common Subtype of Colorectal Cancer

July 09, 2024

Article

Botensilimab plus balstilimab generated responses in relapsed/refractory microsatellite stable metastatic colorectal cancer.

Dana-Farber Cancer Institute Partners With Massachusetts Firefighters to Address Cancer Risks

July 06, 2024

Article

Dana-Farber Cancer Institute is proud to announce the launch of the Direct Connect Partnership with Massachusetts Firefighters, addressing the heightened cancer risk faced by firefighters.